Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes.

Thankamony, A

Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes. [electronic resource] - The Journal of clinical endocrinology and metabolism Feb 2014 - 639-47 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1945-7197

10.1210/jc.2013-3264 doi


Cross-Over Studies
Diabetes Mellitus, Type 1--metabolism
Female
Human Growth Hormone--analogs & derivatives
Humans
Insulin--blood
Insulin Resistance
Insulin-Like Growth Factor I--metabolism
Lipid Metabolism--drug effects
Liver--drug effects
Male
Muscle, Skeletal--drug effects